Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru
PLOS Neglected Tropical Diseases·
- DOI
- 10.1371/journal.pntd.0004398
- PMID
- 26848841
- PMCID
- PMC4746126
- OpenAlex
- W2256356363
- Study type
- Journal article
- Publisher
- Public Library of Science (PLoS)
- Article type
- journal-article
- Integrity
- current
Publication version
This article has a linked preprint
The relationship comes from Crossref version metadata. Compare both records because findings and wording may have changed between versions.
Open linked preprint →Why this research matters now
The findings challenge the assumption of complete lifelong protection from homologous dengue re-infection and provide context for understanding limited vaccine efficacy against DENV-2 in recent trials. The incomplete protection may have implications for dengue transmission dynamics.
Structured evidence summary
Research question
The study investigated whether prior infection with dengue virus serotype 2 (DENV-2) provides complete protection against re-infection with the same serotype, examining this assumption during a 2010-2011 DENV-2 epidemic in Iquitos, Peru.
Study design
The study combined longitudinal cohort data from 1993-2010 to estimate age-dependent DENV antibody prevalence with active surveillance during the 2010-2011 epidemic to identify symptomatic dengue cases and inapparent infections through contact tracing.
Population and setting
The study was conducted in Iquitos, Peru, examining individuals across age groups during a DENV-2 epidemic occurring 15 years after the region's first DENV-2 outbreak.
Main findings
Homologous protection against DENV-2 re-infection was estimated at only 35.1% (95% CI: 0%-65.2%). The age distribution of DENV-2 cases was older than expected based on prior antibody prevalence, and 43% of symptomatic dengue cases had elevated DENV-2 antibodies for years before infection, compared to 76% of inapparent infections.
Public-health relevance
The findings challenge the assumption of complete lifelong protection from homologous dengue re-infection and provide context for understanding limited vaccine efficacy against DENV-2 in recent trials. The incomplete protection may have implications for dengue transmission dynamics.
Important limitations
This summary relies on the supplied single-article abstract and metadata. The original paper is required for decision-grade interpretation of methods, potential confounders, and full discussion of limitations.
GIDS interpretation
This article is discoverable through disease (Dengue), country (Peru), and topic (Vaccination) classifiers. It addresses fundamental immunological assumptions relevant to dengue epidemiology and vaccine development but does not constitute surveillance data.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.